Ignite Creation Date:
2024-05-05 @ 4:44 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00308438
Status:
COMPLETED
Last Update Posted:
2021-05-14
First Post:
2005-09-13
Brief Title:
Safety and Efficacy of ALX-0600 in Subjects With Active Crohns Disease Who Completed Protocol CL0600-008
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohns Disease Who Completed the Pilot Study Protocol CL0600-008
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine whether an investigational compound ALX-0600 is safe and effective in treating Crohns Disease
Detailed Description:
The study is sixteen weeks in duration and there are twelve weeks of once-daily injections into your abdomen or thigh There are a total of five visits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None